1373715-00-4
1373715-00-4 structure
- Name: Luspatercept
- Chemical Name: Luspatercept
- CAS Number: 1373715-00-4
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Stem Cell/Wnt TGF-beta/Smad
- Create Date: 2018-07-18 12:17:14
- Modify Date: 2024-01-11 19:33:09
-
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia[1].
| Name | Luspatercept |
|---|
| Description | Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Luspatercept (0.1-1000 ng/mL) 抑制 A204 细胞中 GDF11 和 GDF8 诱导的 Smad2 和 Smad 3 信号通路[1]。 Luspatcept 与 GDF11，GDF8，activin B，BMP10 和 BMP6 结合[1]。 |
| In Vivo | Luspatercept (0.1-60mg /kg，皮下注射；10mg /kg，静脉注射；每周 2 次，共 8 周) 增加小鼠、大鼠和猴子的红细胞 (RBC) 数量、血红蛋白水平和红细胞堆积[1]。 Luspatercept (10mg /kg，皮下注射，1 次) 降低 C57BL/6 小鼠骨髓和脾脏中的红细胞形成单位 (BFU-Es) 和红血球形成单位 (CFU-Es)[1]。 Luspatercept (10mg /kg，腹腔注射，1 次) 抑制小鼠脾脏 Smad2/3 磷酸化[1]。 Animal Model: C57BL/6 mice[1] Dosage: 0.1, 0.3, 1, 3 and 10 mg/kg Administration: Subcutaneous injection and intravenous injection; 0.1-10 mg/kg (C57BL/6 mice, s.c.), 6-60 mg/kg (Sprague Dawley rats, s.c.), 0.4-30 mg/kg (cynomolgus monkeys, s.c.), 10 mg/kg, (cynomolgus monkeys, i.v.); twice weekly for 8 weeks Result: Dose-dependently increased the level of RBC, hemoglobin and hematocrit in mice, rats and monkeys. |
| References |
| No Any Chemical & Physical Properties |